Activist Hedge Fund Sarissa Takes a Stake in Wounded Biotech Ariad Pharmaceuticals, Inc.

Published: Oct 30, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Oct 29 (Reuters) - Sarissa Capital Management LP, a hedge fund run by investor Carl Icahn's former healthcare lieutenant, has taken a 6.22 percent stake in the wounded biotechnology company Ariad Pharmaceuticals Inc.

Ariad's shares have fallen more than 80 percent since Oct. 9, when it announced that the U.S. Food and Drug Administration had placed a partial hold on patient enrollment in clinical trials of its cancer drug Iclusig due to safety concerns.

Help employers find you! Check out all the jobs and post your resume.

Back to news